References
- D'Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms' tumor. Results of the Third Wilms' Tumor Study. Cancer 1989; 64: 349–360
- Ludwig R, Weirich A, Potter R, et al. Praeoperative Chemotherapie des Nephroblastomas: Vorlaufige Ergebnisse der Therapiestudie SIOP 9/GPO. Klin Padiatr. 1992; 204: 204–213
- Beckwith JB, Palmer N. Histopathology and prognosis of Wilms' tumor. Results of the National Wilms' Tumor Study. Cancer 1978; 41: 1937–1948
- Grundy P, Breslow N, Green DM, Sharpies K, Evans A, D'Angio GJ. Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third Wilms' Tumor Study. J Clin Oncol. 1989; 7: 638–647
- Garaventa A, Hartmann O, Bernard JL, et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 1994; 22: 11–14
- Patzer L, Hempel L, Ringelmann F, et al. Renal function after conditioning therapy for bone marrow transplantation in childhood. Med Pediatr Oncol. 1997; 28: 274–283
- Skinner R, Sharkey M, Pearson ADJ, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol. 1993; 11: 173–190
- Pein F, Michon J, Valteau-Couanet D, et al. High dose (HD) melphalan (M), etoposide (E) and carboplatin (C) with bone marrow transplantation as consolidation therapy (CT) in high risk Wilms' tumors. Med Pediatr Oncol. 1995; 25: 313, 140, Abstract
- Hempel L, Kremens B, Weirich A, Graf N, Zind F, Ludwig R. High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and study. Klin Padiatr. 1996; 208: 186–189
- Pein F, Pinkerton R, Tournade MF, et al. Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study. Group. JClin Oncol. 1993; 11: 1487–1491